Theodoros Foukakis

Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Artiklar

Article: LANCET. 2025;406(10503):603-614
Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
Early Breast Cancer Trialists' Collaborative Group; Early Breast Cancer Trialists' Collaborative Group
Article: BREAST. 2025;82:104489
Optimization of guidelines for Risk Of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
Kjallquist U; Tsiknakis N; Acs B; Margolin S; Kessler LE; Levy S; Ekholm M; Lundgren C; Olsson E; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(6):1117-1124
Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation
Zerdes I; Filis P; Fountoukidis G; El-Naggar AI; Kalofonou F; D'Alessio A; Pouptsis A; Foukakis T; Pentheroudakis G; Ahlgren J; Smith D; Valachis A
Article: BREAST CANCER RESEARCH AND TREATMENT. 2025;211(2):385-397
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
Shinn E; Zahrieh D; Demichele A; Zdenkowski N; Lemieux J; Mao J; Bjelic-Radisic V; Naughton MJ; Pfeiler G; Gelmon K; Balko JM; Egle D; Zoppoli G; Traina T; Jimenez MM; Novoa SA; Haddad T; Chan A; Ring A; Wolff A; Symmans WF; Ponce Lorenzo J; Sabanathan D; Burstein HJ; Nowecki ZI; Pristauz-Telsnigg G; Brufsky A; Bellet-Ezquerra M; Foukakis T; Novik Y; Rubovszky G; Singer CF; Muehlbacher K; Filho OM; Goulioti T; Law E; Partridge AH; Carey LA; Zoroufy A; Hlauschek D; Fesl C; Mayer EL; Gnant M
Article: EUROPEAN JOURNAL OF RADIOLOGY. 2025;186:112062
Patient experience and healthcare cost aspects of vacuum-assisted excision of breast lesions. A report from the Swedish VAE randomized clinical trial
Zouzos A; Fredriksson I; Karakatsanis A; Foukakis T; Strand F
Article: INTERNATIONAL JOURNAL OF CANCER. 2025;156(8):1621-1633
Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer
Kouvaraki M; Zerdes I; Sifakis EG; Sarafidis M; Matikas A; Tzoras E; Kjallquist U; Stathopoulou K; Lovrot J; Alkodsi A; Hartman J; Sotiriou C; Richard F; Hatschek T; Herold N; Bergh J; Rassidakis GZ; Foukakis T
Article: JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. 2025;23(4):e247093
Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study
Boman C; Tranchell C; Liu X; Bergman LE; Toli MA; Bergh J; Foukakis T; Matikas A
Article: BREAST CANCER RESEARCH. 2025;27(1):35
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Dent R; Cortes J; Park YH; Munoz-Couselo E; Kim S-B; Sohn J; Im S-A; Holgado E; Foukakis T; Kuemmel S; Yearley J; Wang A; Nebozhyn M; Huang L; Cristescu R; Jelinic P; Karantza V; Schmid P
Article: NPJ BREAST CANCER. 2025;11(1):23
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial
Zerdes I; Matikas A; Mezheyeuski A; Manikis G; Acs B; Johansson H; Boyaci C; Boman C; Poncet C; Ignatiadis M; Bai Y; Rimm DL; Cameron D; Bonnefoi H; Bergh J; Macgrogan G; Foukakis T
Article: EJSO. 2025;51(3):109587
Long-term outcome for neoadjuvant versus adjuvant chemotherapy in early breast cancer and the prognostic impact of nodal therapy response: A population-based study
Liu X; Bergman LE; Boman C; Foukakis T; Matikas A
Article: LANCET REGIONAL HEALTH-EUROPE. 2025;49:101162
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial
Matikas A; Papakonstantinou A; Loibl S; Steger GG; Untch M; Johansson H; Tsiknakis N; Hellstrom M; Greil R; Moebus V; Gnant M; Bergh J; Foukakis T
Article: EUROPEAN JOURNAL OF RADIOLOGY. 2025;183:111895
Effect of needle size on outcomes of vacuum-assisted excision of breast lesions. A randomized controlled trial
Zouzos A; Fredriksson I; Karakatsanis A; Aristokleous I; Foukakis T; Strand F
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2024;391(21):1981-1991
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid P; Cortes J; Dent R; McArthur H; Pusztai L; Kuemmel S; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Im S-A; Untch M; Fasching PA; Mouret-Reynier M-A; Foukakis T; Ferreira M; Cardoso F; Zhou X; Karantza V; Tryfonidis K; Aktan G; O'Shaughnessy J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(26):3077-3082
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Matikas A; Moebus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstroem P; Schmatloch S; Johansson H; Hellstroem M; Brandberg Y; Gnant M; Loibl S; Foukakis T; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2024;131(4):718-728
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
Boman C; Liu X; Eriksson Bergman L; Sun W; Tranchell C; Toli MA; Acs B; Bergh J; Foukakis T; Matikas A
Journal article: ANNALS OF ONCOLOGY. 2024;35:s356
A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
Foukakis T; Naume B; Karakatsanis A; Andersson A; Barnekow E; Kessler LE; Einbeigi Z; Engebraten O; Killander F; Linderholm BK; Schiza A; Valachis A; Bergh J; Villacampa G; Zouzos A; Hellstrom M; Hartman J; Matikas A
Journal article: ANNALS OF ONCOLOGY. 2024;35:s355-s356
EORTC-2129-BCG: Elacestrant for treating ER+/HER2-breast cancer patients with ctDNA relapse (TREAT ctDNA)
Ignatiadis M; Saloustros E; Joaquim A; Casas JG; Kelly CM; Razis E; Lambertini M; Foukakis T; Fehr M; van Oordt CWM-VDH; Crestani TA; Simon SP; Bussels B; Hanssens M; Neven P; Xenophontos E; Meyskens T; Bidard FC; Poncet C; Janni W
Journal article: ANNALS OF ONCOLOGY. 2024;35:s262
Comprehensive cancer genome profiling as supportive tool for treatment decision-making in patients with metastatic solid tumors: Real-world evidence-based meta-analysis and nationwide cancer registry data implementation
Zerdes I; Filis P; Fountoukidis G; El-Naggar AI; Kalofonou F; D'Alessio A; Pouptsis A; Foukakis T; Pentheroudakis G; Ahlgren J; Smith D; Valachis A
Journal article: ANNALS OF ONCOLOGY. 2024;35:s1112
Grading the evidence for physical activity and all outcomes in cancer survivors: An umbrella review of more than 700 meta-analytic associations
Filis P; Markozannes G; Chan D; Mauri D; Foukakis T; Matikas A; Droufakou S; Pentheroudakis G; Tsilidis K
Article: NATURE MEDICINE. 2024;30(9):2623-2630
AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial
Salim M; Liu Y; Sorkhei M; Ntoula D; Foukakis T; Fredriksson I; Wang Y; Eklund M; Azizpour H; Smith K; Strand F
Article: IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS. 2024;28(9):5312-5322
Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images
Tsiknakis N; Manikis G; Tzoras E; Salgkamis D; Vidal JM; Wang K; Zaridis D; Sifakis E; Zerdes I; Bergh J; Hartman J; Acs B; Marias K; Foukakis T
Article: SCIENTIFIC REPORTS. 2024;14(1):18275
Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue
Salgkamis D; Sifakis EG; Agartz S; Wirta V; Hartman J; Bergh J; Foukakis T; Matikas A; Zerdes I
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2024;2024:1-5
Ensuring Model Fairness via Stratified Training: TP53 Mutation Prediction with Estrogen Receptor Stratification in Breast Histopathology.
Tsiknakis N; Wang K; Salgkamis D; Tzoras E; Manikis GC; Sifakis E; Bergh J; Zerdes I; Marias K; Matikas A; Foukakis T
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16_suppl):521
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.
Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
Article: NATURE COMMUNICATIONS. 2024;15(1):3837
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
Wang K; Zerdes I; Johansson HJ; Sarhan D; Sun Y; Kanellis DC; Sifakis EG; Mezheyeuski A; Liu X; Loman N; Hedenfalk I; Bergh J; Bartek J; Hatschek T; Lehtio J; Matikas A; Foukakis T
Journal article: CANCER RESEARCH. 2024;84(9_Supplement):ps12-09-ps12-09
Abstract PS12-09: Capivasertib plus cyclin-dependent kinase 4/6 inhibitor and fulvestrant in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: updated Phase 1b analysis from CAPItello-292
Hamilton E; Neven P; Pistilli B; Beeram M; Borges V; Campone M; Guimarães JLM; Foukakis T; Kodahl AR; Lau P; Lim E; Ługowska I; Rychlik G; Gresty C; Miller C; Sommavilla R; Sudhan D; Rugo H
Journal article: CANCER RESEARCH. 2024;84(9_Supplement):lbo1-01-lbo1-01
Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
Schmid P; Cortés J; Dent R; Pusztai L; McArthur H; Küemmel S; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Mouret-Reynier M-A; Ferreira M; Im S-A; Cardoso F; Ding Y; Pan W; Tryfonidis K; O'Shaughnessy J
Journal article: ESMO OPEN. 2024;9:103099
111MO Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase III PANTHER trial
Foukakis T; Matikas A; Möbus V; Greil R; Andersson A; Steger GG; Untch M; Fornander T; Malmstrom P; Johansson H; Hellström M; Brandberg Y; Gnant MI; Loibl S; Bergh J
Journal article: ESMO OPEN. 2024;9:103131
144P Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: A population-based study
Boman CE; Tranchell C; Liu X; Bergman LE; Toli MA; Bergh J; Foukakis T; Matikas A
Journal article: ESMO OPEN. 2024;9:103074
68P Application of a machine learning model for identifying an ultra-low risk group of early breast cancer patients
Sarafidis M; Sifakis EG; Bergh J; Foukakis T; Matikas A
Journal article: ESMO OPEN. 2024;9:103124
137P Adherence to and optimization of guidelines for risk of recurrence/Prosigna testing using a machine learning model: A Swedish multicenter study
Kjällquist U; Tsiknakis N; Acs B; Margolin S; Ekholm M; Kessler LE; Lundgren C; Garcia SG; Olsson EJ; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
Journal article: ESMO OPEN. 2024;9:103116
129P Adherence to adjuvant endocrine therapy in the era of combination treatments: A population-based study
Bergman LE; Matikas A; Liu X; Foukakis T
Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: BREAST CANCER RESEARCH. 2024;26(1):38
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindstroem LS; Tobin NP
Article: BREAST CANCER RESEARCH. 2024;26(1):24
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Ronnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Article: BREAST CANCER RESEARCH. 2024;26(1):4
Identification of a Notch transcriptomic signature for breast cancer
Braune E-B; Geist F; Tang X; Kalari K; Boughey J; Wang L; Leon-Ferre RA; D'Assoro AB; Ingle JN; Goetz MP; Kreis J; Wang K; Foukakis T; Seshire A; Wienke D; Lendahl U
Journal article: ECLINICALMEDICINE. 2024;67:102335
Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden.
Rodriguez-Wallberg KA; Kieler H; Foukakis T; Li J; Gissler M; Oberg AS; Bergh J; Lundberg FE
Article: ECLINICALMEDICINE. 2024;67:102335
Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden
Rodriguez-Wallberg KA; Kieler H; Foukakis T; Li J; Gissler M; Oberg AS; Bergh J; Lundberg FE
Article: BMJ OPEN. 2023;13(12):e078023
ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study
Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennstrom L; Frisk P; Moerse H; Eloranta S
Journal article: MOLECULAR CANCER THERAPEUTICS. 2023;22(12_Supplement):b013
Abstract B013: Identification of a Notch transcriptomic signature for breast cancer
Braune E-B; Geist F; Tang X; Kalari K; Boughey J; Wang L; Leon-Ferre RA; D’Assoro AB; Ingle JN; Goetz MP; Wang K; Foukakis T; Seshire A; Wienke D; Lendahl U
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(33):5118-5130
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M; Park H; Prat A; Isaacs C; Bajetta E; Balko JM; Bellet-Ezquerra M; Bliss J; Burstein H; Cardoso F; Fohler H; Foukakis T; Gelmon KA; Goetz M; Haddad TC; Iwata H; Jassem J; Lee S-C; Linderholm B; Los M; Mamounas EP; Miller KD; Morris PG; Munzone E; Gal-Yam EN; Ring A; Shepherd L; Singer C; Thomssen C; Tseng L-M; Valagussa P; Winer EP; Wolff AC; Zoppoli G; Machacek-Link J; Schurmans C; Huang X; Gauthier E; Fesl C; Dueck AC; DeMichele A; Gnant M
Article: JOURNAL OF CLINICAL INVESTIGATION. 2023;133(22):e166666
FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters
Li M; Nishimura T; Takeuchi Y; Hongu T; Wang Y; Shiokawa D; Wang K; Hirose H; Sasahara A; Yano M; Ishikawa S; Inokuchi M; Ota T; Tanabe M; Tada K-I; Akiyama T; Cheng X; Liu C-C; Yamashita T; Sugano S; Uchida Y; Chiba T; Asahara H; Nakagawa M; Sato S; Miyagi Y; Shimamura T; Nagai LAE; Kanai A; Katoh M; Nomura S; Nakato R; Suzuki Y; Tojo A; Voon DC; Ogawa S; Okamoto K; Foukakis T; Gotoh N
Journal article: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:108455
O-59 Preclinical evaluation of [89Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)
Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran T
Journal article: ANNALS OF ONCOLOGY. 2023;34:s1257
Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study
Schmid P; Cortes J; Dent RA; Pusztai L; McArthur HL; Kummel S; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Reynier MAM; Ferreira MIR; Im SA; Cardoso F; Ding Y; Pan W; Tryfonidis KE; O'Shaughnessy J
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2023;2023:1-4
Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis
Tsiknakis N; Tzoras E; Zerdes I; Manikis GC; Acs B; Hartman J; Hatschek T; Foukakis T; Marias K
Journal article: ESMO OPEN. 2023;8(1):101395
206P Capivasertib (C) + palbociclib (P) and fulvestrant (F) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase Ib data from CAPItello-292
Neven P; Hamilton E; Pistilli B; Borges V; Campone M; Foukakis T; Kodahl AR; Lau PKH; Lim E; Lugowska I; Collins J; Gresty C; Miller C; Sommavilla R; Sudhan D; Rugo HS
Journal article: ESMO OPEN. 2023;8(1):101447
259TiP Treatment of oligometastatic breast cancer (OMBC): A randomised phase III trial comparing stereotactic ablative radiotherapy (SABR) and systemic treatment with systemic treatment alone as first-line treatment - TAORMINA
Linderholm BK; Valachis A; Flote VG; Poortmans P; Person OK; Niligal-Yam E; O'Reilly S; Duane F; Marinko T; Ekholm M; Andersson A; Bergqvist J; Foukakis T; Kadum M; Kulbacka-Ortiz K; Nilsson-Ek A; Visani L; Lundstedt D; Meattini I
Journal article: BREAST. 2023;68:s63-s64
P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Kümmel S; Schmid P; Harbeck N; Takahashi M; Untch M; Boileau J-F; Cortes J; McArthur H; Dent R; O’Shaughnessy J; Pusztai L; Foukakis T; Park YH; Hui R; Cardoso F; Denkert C; Zhu Y; Pan W; Karantza V; Fasching P
Journal article: CANCER RESEARCH. 2023;83(5_Supplement):pd3-01-pd3-01
Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
McArthur H; Cortés J; Dent R; O’Shaughnessy J; Pusztai L; Küemmel S; Foukakis T; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Denkert C; Zhu Y; Ding Y; Pan W; Schmid P
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540
Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Gryback P; Bjohle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Min ATH; Lovrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Journal article: EUROPEAN JOURNAL OF CANCER. 2022;175:s40
126 (PB-039) Poster A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients
Karanasiou G; Grigoriadis G; Alexandraki A; Antoniades A; Brown C; Bucur A; Cipolla C; Economopoulou P; Foukakis T; Goossens J; Keramida K; Lakkas L; Marias K; Naka K; Papakonstantinou A; Pravettoni G; Ribnikar D; Šeruga B; Zacharia M; Tsiknakis M; Fotiadis DI
Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56
Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
Boman C; Kessler LE; Bergh J; Matikas A; Foukakis T
Article: MOLECULAR ONCOLOGY. 2022;16(12):2413-2431
Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer
Wang K; Li L; Franch-Exposito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Article: CANCERS. 2022;14(11):2615
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
Kjallquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Hernandez SG; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
Journal article: CANCER RESEARCH. 2022;82(4_Supplement):p4-12-01-p4-12-01
Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial
Shinn E; Zahrieh D; DeMichele A; Zdenkowski N; Lemieux J; Mao J; Bjelic-Radisic V; Naughton M; Pfeiler G; Gelmon K; Mayer I; Egle D; Zoppoli G; Traina T; Jiménez MM; Novoa SA; Haddad T; Chan A; Ring AE; Wolff A; Lorenzo JJ; Sabanathan D; Burstein H; Nowecki ZI; Pristauz-Telsnigg G; Brufsky A; Bellet-Ezquerra M; Foukakis T; Novik Y; Rubovszky G; Muehlbacher K; Metzger O; Goulioti T; Law E; Partridge A; Carey L; Zoroufy A; Hlauschek D; Fesl C; Mayer E; Gnant M
Journal article: CANCER RESEARCH. 2022;82(4):p3-18-03-p3-18-03
Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)
Wang K; Duinmeijer A; Matikas A; Altena R; Johansson H; Fredholm H; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):144
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Journal article: BJS-BRITISH JOURNAL OF SURGERY. 2021;108(9):1120-1125
Axillary evaluation in ductal cancer in situ of the breast: challenging the diagnostic accuracy of clinical practice guidelines
Karakatsanis A; Charalampoudis P; Pistioli L; Di Micco R; Foukakis T; Valachis A
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2021;7(9):1360-1367
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer A Phase 2 Randomized Clinical Trial
Hatschek T; Foukakis T; Bjohle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Gryback P; Hellstrom M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
Article: ESMO OPEN. 2021;6(4):100217
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
Eriksson M; Reichardt P; Joensuu H; Krarup-Hansen A; Hagberg O; Hohenberger P; Hagberg H; Hansson L; Foukakis T; Pulkkanen K; Bauer S; Goplen D; Rossen PB; Hall KS
Article: CLINICAL NUTRITION. 2021;40(5):3370-3378
Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study
Wang K; Wu Q; Li Z; Reger MK; Xiong Y; Zhong G; Li Q; Zhang X; Li H; Foukakis T; Xiang T; Zhang J; Ren G
Article: ESMO OPEN. 2021;6(2):100076
bPrognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjohle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellstrom M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):21
Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation
Wang K; Li Z; Chen X; Zhang J; Xiong Y; Zhong G; Shi Y; Li Q; Zhang X; Li H; Xiang T; Foukakis T; Radivoyevitch T; Ren G
Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387
Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience
Kessler LE; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: JAMA ONCOLOGY. 2020;6(10):1581-1588
External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms
Salim M; Wahlin E; Dembrower K; Azavedo E; Foukakis T; Liu Y; Smith K; Eklund M; Strand F
Journal article: NPJ BREAST CANCER. 2020;6(1)
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study
Wang K; Sun J-Z; Wu Q-X; Li Z-Y; Li D-X; Xiong Y-F; Zhong G-C; Shi Y; Li Q; Zheng J; Shivappa N; Hebert JR; Foukakis T; Zhang X; Li H-Y; Xiang T-X; Ren G-S
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651
Chemotherapy use near the end-of-life in patients with metastatic breast cancer
Kessler LE; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):590
One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.
Brandberg Y; Foukakis T; Andersson A; Bjohle J; Bosch A; Carlsson L; Einbeigi Z; Fredholm H; Isaksson-Friman E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Bergh JCS; Hatschek T
Article: ANNALS OF ONCOLOGY. 2020;31(5):569-581
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Schmid P; Salgado R; Park YH; Munoz-Couselo E; Kim SB; Sohn J; Im S-A; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortes J; Loi S
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(1):87-96
Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
Brandberg Y; Johansson H; Hellstrom M; Gnant M; Mobus V; Greil R; Foukakis T; Bergh J
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020;106(5):958-967
Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial
Bosma SCJ; Leij F; Vreeswijk S; de Maaker M; Wesseling J; van de Vijver M; Scholten A; Rivera S; Bourgier C; Auzac G; Foukakis T; Lekberg T; Bongard D; Loo C; Rutgers E; Bartelink H; Elkhuizen PHM
Article: CANCER. 2020;126(6):1175-1182
Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer: Results From the Phase 3 PANTHER Trial
Papakonstantinou A; Matikas A; Bengtsson NO; Malmstrom P; Hedayati E; Steger G; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(9):810-821
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid P; Cortes J; Pusztai L; McArthur H; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J
Journal article: EJSO. 2020;46(2):e63
Axillary Evaluation in the Setting of a Preoperative Ductal Cancer in Situ (DCIS) Diagnosis. Do Guidelines (Mis)Guide?
Karakatsanis A; Valachis A; Pistioli L; Charalampoudis P; DiMicco R; Foukakis T; Wärnberg F
Article: ACTA ONCOLOGICA. 2020;59(1):75-81
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer
Papakonstantinou A; Hedayati E; Hellstrom M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Article: NPJ BREAST CANCER. 2020;6:36
Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study.
Wang K; Sun J-Z; Wu Q-X; Li Z-Y; Li D-X; Xiong Y-F; Zhong G-C; Shi Y; Li Q; Zheng J; Shivappa N; Hébert JR; Foukakis T; Zhang X; Li H-Y; Xiang T-X; Ren G-S
Article: ONCOLOGIST. 2020;25(1):23-32
Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial
Mijwel S; Bolam KA; Gerrevall J; Foukakis T; Wengstrom Y; Rundqvist H
Journal article: ANNALS OF ONCOLOGY. 2019;30:v853-v854
LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Schmid P; Cortés J; Dent R; Pusztai L; McArthur HL; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Jia L; Karantza V; Zhao J; Aktan G; O’Shaughnessy J
Journal article: ANNALS OF ONCOLOGY. 2019;30:v136
373P Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study
Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
Article: CANCERS. 2019;11(10):E1479-1479
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Journal article: ANNALS OF ONCOLOGY. 2019;30:v86-v87
258P Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Papakonstantinou A; Matikas A; Hellström M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
Journal article: 2019
Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim S-B; Sohn J; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Article: BRITISH JOURNAL OF CANCER. 2019;120(10):959-967
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Mueller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J
Article: LANCET. 2019;393(10179):1440-1452
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
Boddington C; Bradley R; Braybrooke J; Burrett J; Clarke M; Davies C; Davies L; Dodwell D; Duane F; Evans V; Gettins L; Godwin J; Gray R; Hills R; James S; Liu H; Liu Z; MacKinnon E; Mannu G; McGale P; McHugh T; Morris P; Pan H; Peto R; Read S; Taylor C; Wang Y; Wang Z; Bradley R; Braybrooke J; Gray R; Bergh J; Peto R; Gray R; Bradley R; Braybrooke J; Liu Z; Peto R; Davies L; Dodwell D; McGale P; Pan H; Taylor C; Barlow W; Bliss J; Bruzzi P; Cameron D; Fountzilas G; Loibl S; Mackey J; Martin M; Del Mastro L; Moebus V; Nekljudova V; De Placido S; Swain S; Untch M; Pritchard KI; Bergh J; Norton L; Fasching P; Harbeck N; Untch M; Piedbois P; Gnant M; Steger G; Di Leo A; Dolci S; Francis P; Larsimont D; Nogaret JM; Philippson C; Piccart-Gebhart MJ; Linn S; Peer P; Tjan-Heijnen V; Vliek S; Mackey J; Martin M; Slamon D; Bartlett JMS; Bramwell VH; Chen BE; Chia SKL; Gelmon K; Goss PE; Levine MN; Parulekar W; Pater JL; Pritchard KI; Rakovitch E; Shepherd LE; Tu D; Whelan T; Berry D; Broadwater G; Cirrincione C; Muss H; Norton L; Weiss RB; Shan Y; Shao YF; Wang X; Xu B; Zhao DB; Bartelink H; Bijker N; Bogaerts J; Cardoso F; Cufer T; Julien JP; Poortmans PM; Rutgers E; van de Velde CJH; Carrasco E; Martin M; Segui MA; Blohmer JU; Costa SD; Gerber B; Jackisch C; Loibl S; Nekljudova V; von Minckwitz G; Bruzzi P; Giuliano M; De laurentiis M; De Placido S; Del Mastro L; Bamia C; Fountzilas G; Koliou G-A; Mavroudis D; A'Hern R; Bliss J; Cameron D; Ellis P; Kilburn L; Morden J; Yarnold JR; Sadoon M; Tulusan AH; Anderson S; Bass G; Costantino J; Dignam J; Fisher B; Geyer C; Mamounas EP; Paik S; Redmond C; Swain S; Wickerham L; Wolmark N; Del Mastro L; Venturini M; Bighin C; Bruzzi P; Del Mastro L; Pastorino S; Pronzato P; Sertoli MR; Barlow W; Bergh J; Foukakis T; Pritchard KI; Swain S; Cameron D; Albain K; Anderson S; Arriagada R; Barlow W; Bartlett J; Bergsten-Nordstrom E; Bliss J; Boccardo F; Bradley R; Brain E; Braybrooke J; Carey L; Clarke M; Coates A; Coleman R; Correa C; Costantino J; Cuzick J; Davidson N; Davies C; Davies L; Di Leo A; Dodwell D; Dowsett M; Duane F; Ewertz M; Forbes J; Francis P; Gelber R; Gnant M; Goldhirsch A; Goodwin P; Gray R; Hayes D; Hill C; Ingle J; Jagsi R; Janni W; Liu Z; Loibl S; MacKinnon E; Mannu G; Martin M; McGale P; Mukai H; Nekljudova V; Norton L; Ohashi Y; Paik S; Pan H; Peto R; Piccart M; Pierce L; Poortmans P; Raina V; Ravdin P; Rea D; Regan M; Robertson J; Rutgers E; Slamon D; Sparano J; Steger G; Taylor C; Tutt A; Viale G; Wang X; Whelan T; Wilcken N; Wolmark N; Wood W; Zambetti M
Article: BREAST CANCER RESEARCH. 2019;21(1):34
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours
Lundberg A; Lindstroem LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;172(3):703-712
Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34years longitudinal data from the Stockholm-Gotland cancer registry
Falato C; Taylor SK; Szulkin R; Nordblom A; Eriksson L; Sofiadis A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
Article: CELL. 2018;173(4):879-893.e13
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Kim C; Gao R; Sei E; Brandt R; Hartman J; Hatschek T; Crosetto N; Foukakis T; Navin NE
Article: EJNMMI RESEARCH. 2018;8(1):25
Treatment response assessment with (R)-[¹¹CPAQ PET in the MMTV-PyMT mouse model of breast cancer
Tegnebratt T; Lu L; Eksborg S; Chireh A; Damberg P; Nikkhou-Aski S; Foukakis T; Rundqvist H; Holmin S; Kuiper RV; Samen E
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Journal article: LANCET ONCOLOGY. 2018;19(1):127-138
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M; Luo W; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Hitre E; Graas M-P; Simoncini E; Kamby C; Thompson A; Loibl S; Gavila J; Kuroi K; Marth C; Mueller B; O'Reilly S; Di Lauro V; Gombos A; Ruhstaller T; Burstein H; Ribi K; Bernhard J; Viale G; Maibach R; Rabaglio-Poretti M; Gelber RD; Coates AS; Di Leo A; Regan MM; Goldhirsch A
Article: CLINICAL CANCER RESEARCH. 2017;23(24):7512-7520
Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Lundberg A; Lindstrom LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: CLINICAL CANCER RESEARCH. 2017;23(23):7225-7231
PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients
Tobin NP; Lundberg A; Lindstrom LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Ferno M; Czene K; Perou CM; Bergh J; Hatschek T
Article: CANCER CELL. 2017;32(5):669-683.e5
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon A; Tyrakis PA; Macias D; Velica P; Rundqvist H; Fitzpatrick S; Vojnovic N; Phan AT; Loman N; Hedenfalk I; Hatschek T; Lovrot J; Foukakis T; Goldrath AW; Bergh J; Johnson RS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(45):E9635-E9644
Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production
Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
Journal article: ANNALS OF ONCOLOGY. 2017;28:v68
219P Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Matikas A; Lövrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
Journal article: ANNALS OF ONCOLOGY. 2017;28:v507
1422O CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians’ and patients’ scoring of toxicity in the “Panther trial”
Brandberg Y; Loibl S; Foukakis T; Johansson H; Gnant M; Singer CF; von Minckwitz G; Bengtsson N-O; Karlsson E; Mlineritsch B; Hellström M; Steger G; Carlsson L; Egle D; Greil R; Bergh J
Journal article: ANNALS OF ONCOLOGY. 2017;28:v95
288P Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register
Falato C; Eriksson L; Sofiadis A; Taylor SK; Nordblom A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Article: NATURE COMMUNICATIONS. 2017;8(1):228
Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer
Gao R; Kim C; Sei E; Foukakis T; Crosetto N; Chan L-K; Srinivasan M; Zhang H; Meric-Bernstam F; Navin N
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e12036
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 (SBG 2004-1) randomized trial of tailored dose adjuvant chemotherapy for early breast cancer.
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Carlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm BK; Lindman H; Malmstrom P; Villman KK; Foukakis T; Bergh JCS
Article: LAKARTIDNINGEN. 2017;114:EEIS
[Chemotherapy and targeted drugs to reinforce each other].
Foukakis T; Bergh J
Article: ONCOTARGET. 2016;7(46):74966-74978
Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes
Vardaki I; Ceder S; Rutishauser D; Baltatzis G; Foukakis T; Panaretakis T
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2016;316(18):1888-1896
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer A Randomized Clinical Trial
Foukakis T; von Minckwitz G; Bengtsson N-O; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellstrom M; Johansson H; Anderson H; Malmstrom P; Gnant M; Greil R; Mobus V; Bergh J
Article: CLINICAL CANCER RESEARCH. 2016;22(10):2417-2426
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Tobin NP; Wennmalm K; Lindstrom LS; Foukakis T; He L; Genove G; Ostman A; Landberg G; Betsholtz C; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(14):1573-1579
Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Journal article: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(14):1387
A 21-Gene Expression Assay in Breast Cancer.
Sparano JA
Article: MOLECULAR ONCOLOGY. 2016;10(4):517-525
Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse
Falato C; Tobin NP; Lorent J; Lindstrom LS; Bergh J; Foukakis T
Article: MOLECULAR ONCOLOGY. 2015;9(7):1384-1391
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer
Foukakis T; Lovrot J; Sandqvist P; Xie H; Lindstrom LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh J
Article: LANCET. 2015;386(9992):433-443
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15_suppl):e22090
Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer.
Falato C; Tobin N; Lorent J; Lindström LS; Bergh JCS; Foukakis T
Article: ACTA ONCOLOGICA. 2015;54(4):522-529
A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden
Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Journal article: RADIOTHERAPY AND ONCOLOGY. 2015;115:s188-s189
OC-0391: First results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial
Bosma SCJ; Van der Leij F; Van de Vijver MJ; Rivera S; Foukakis T; Van den Bongard HJGD; Vreeswijk SAOJ; Bartelink H; Rutgers EJ; Elkhuizen PHM
Article: RADIOTHERAPY AND ONCOLOGY. 2015;114(3):322-327
First results of the preoperative accelerated partial breast irradiation (PAPBI) trial
van der Leij F; Bosma SCJ; van de Vijver MJ; Wesseling J; Vreeswijk S; Rivera S; Bourgier C; Garbay J-R; Foukakis T; Lekberg T; van den Bongard DHJGD; van Vliet-Vroegindeweij C; Bartelink H; Rutgers EJ; Elkhuizen PHM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;147(2):407-414
Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer
Falato C; Lorent J; Tani E; Karlsson E; Wright PK; Bergh J; Foukakis T
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2014;74(3):549-558
Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide
von Stedingk H; Xie H; Hatschek T; Foukakis T; Ryden A; Bergh J; Rydberg P
Journal article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(1):86-87
Thyroid hormone inactivation in gastrointestinal stromal tumors.
Maynard MA; Huang SA
Article: BRITISH JOURNAL OF CANCER. 2014;110(5):1378-1384
Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
Colzani E; Johansson ALV; Liljegren A; Foukakis T; Clements M; Adolfsson J; Hall P; Czene K
Article: BMC CANCER. 2013;13:473
Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies
Milosevic J; Klinge J; Borg A-L; Foukakis T; Bergh J; Tobin NP
Article: JOURNAL OF SURGICAL ONCOLOGY. 2012;106(8):981-986
Anaplastic carcinoma of the thyroid gland: Treatment and outcome over 13 years at one institution
Segerhammar I; Larsson C; Nilsson I-L; Backdahl M; Hoog A; Wallin G; Foukakis T; Zedenius J
Article: ANNALS OF ONCOLOGY. 2012;23:x349-x353
When to order a biopsy to characterise a metastatic relapse in breast cancer
Foukakis T; Astrom G; Lindstrom L; Hatschek T; Bergh J
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2012;308(2):147-156
Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma The ESPAC-3 Periampullary Cancer Randomized Trial
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Olah A; Rawcliffe CL; Verbeke CS; Campbell F; Buechler MW
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15_suppl):e11510
Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.
Kessler L; Bergh J; Foukakis T
Journal article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15_suppl):10083
A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.
Alm D; Linder Stragliotto C; Folin A; Bergh J; Foukakis T
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2012;166(4):657-667
Proteomic profiling of follicular and papillary thyroid tumors
Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Hoog A; Auer G; Lehtio J; Larsson C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;130(2):553-560
Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden
Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Article: THYROID. 2010;20(10):1067-1076
Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca²⁺-Binding Protein S100A6 in Papillary Thyroid Carcinoma
Sofiadis A; Dinets A; Orre LM; Branca RM; Juhlin CC; Foukakis T; Wallin G; Hoog A; Hulchiy M; Zedenius J; Larsson C; Lehtio J
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2009;35(2):369-374
Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy
Sofiadis A; Tani E; Foukakis T; Kjellman P; Skoog L; Hoog A; Wallin G; Zedenius J; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2008;15(3):801-815
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma
Lee J-J; Au AYM; Foukakis T; Barbaro M; Kiss N; Clifton-Bligh R; Staaf J; Borg A; Delbridge L; Robinson BG; Wallin G; Hoog A; Larsson C
Article: JOURNAL OF PATHOLOGY. 2008;215(1):87-96
Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness
Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
Article: ENDOCRINE-RELATED CANCER. 2007;14(2):381-391
A PCR-based expression signature of malignancy in follicular thyroid tumors
Foukakis T; Gusnanto A; Au AYM; Hoog A; Lui W-O; Larsson C; Wallin G; Zedenius J
Article: THYROID. 2007;17(4):289-301
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models
Lee J-J; Foukakis T; Hashemi J; Grimelius L; Heldin N-E; Wallin G; Rudduck C; Lui W-O; Hoog A; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2007;14(1):125-134
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma
Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Hoog A; Clark GJ; Ekstrom TJ; Backdahl M; Farnebo F; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2006;91(3):1143-1149
The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARγ fusion
Foukakis T; Au AYM; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui WO; Zedenius J; Larsson C
Article: TUMOR BIOLOGY. 2006;27(4):211-220
Molecular markers for discrimination of benign and malignant follicular thyroid tumors
Fryknas M; Wickenberg-Bolin U; Goransson H; Gustafsson MG; Foukakis T; Lee J-J; Landegren U; Hoog A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
Article: ONCOGENE. 2005;24(8):1467-1476
Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene
Lui WO; Foukakis T; Lidén J; Thoppe SR; Dwight T; Höög A; Zedenius J; Wallin G; Reimers M; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(1):141-149
Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors
Foukakis T; Thoppe SR; Lagercrantz S; Dwight T; Weng WH; Svensson A; Höög A; Zedenius J; Wallin G; Lui WO; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2003;88(9):4440-4445
Involvement of the PAX8/peroxisome proliferator-activated receptor γ rearrangement in follicular thyroid tumors
Dwight T; Thoppe SR; Foukakis T; Lui WO; Wallin G; Höög A; Frisk T; Larsson C; Zedenius J
Article: GENES CHROMOSOMES & CANCER. 2002;35(1):74-80
Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer
Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1992;33(4):861-869
Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer
Lee J-J; Geli J; Larsson C; Wallin G; Karimi M; Zedenius J; Hoog A; Foukakis T
Visa fler

Alla övriga publikationer

Editorial comment: ANNALS OF ONCOLOGY. 2025;36(6):603-605
Neoadjuvant treatment of HER2-positive breast cancer: has the era of antibody-drug conjugates arrived?
Papakonstantinou A; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2025;15:1469982
The interplay between the immune response and neoadjuvant therapy in breast cancer
Thomas N; Foukakis T; Willard-Gallo K
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2025;207:104602
Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations
Filis P; Markozannes G; Chan DSM; Mauri D; Foukakis T; Matikas A; Droufakou S; Pentheroudakis G; Tsilidis K
Review: CANCER TREATMENT REVIEWS. 2025;132:102853
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer
Bartsch R; Cameron D; Ciruelos E; Criscitiello C; Curigliano G; Duhoux FP; Foukakis T; Gligorov J; Harbeck N; Levasseur N; Okines A; Penault-Llorca F; Mueller V
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(16)
Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial
Matikas A; Gnant M; Johansson H; Untch M; Tsiknakis N; Greil R; Loibl S; Foukakis T; Bergh JCS
Conference publication: ESMO OPEN. 2024;9:103031
23P Longitudinal evaluation of PAM50 molecular subtypes in patients receiving neoadjuvant HER2-targeted therapy in the PREDIX HER2 trial
Zhu Y; Sifakis EG; Wang K; Zerdes I; Bergh J; Hatschek T; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103063
56P Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: A secondary analysis of the phase II PREDIX HER2 trial
Zerdes I; Wang K; Salgkamis D; Zhu Y; Sifakis EG; Acs B; Hartman J; Hatschek T; Bergh J; Matikas A; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103110
122P Primary results and biomarker analysis from PREDIX LumB: A prospective randomized phase II trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer
Matikas A; Bjöhle J; Barnekow E; Isakssonfriman E; Zouzos A; Tzoras E; Johansson H; Margolin S; Acs B; Boyaci C; Sun W; Zerdes I; Kessler LE; Grybäck P; Hellström M; Hartman J; Brandberg Y; Bergh J; Hatschek T; Foukakis T
Conference publication: ESMO OPEN. 2024;9:103075
69P Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides
Tsiknakis N; Salgkamis D; Tzoras E; Wang K; Liu X; Manikis G; Sifakis EG; Bergh J; Marias K; Zerdes I; Matikas A; Foukakis T
Conference publication: CANCER RESEARCH. 2024;84(9):po4-01-05-po4-01-05
The prognostic importance of biological pathway enrichment patterns in trastuzumab-treated early HER2-positive breast cancer
Ronnlund C; Yang Q; Schagerholm C; Foukakis T; Fredriksson I; Chen X; Robertson S; Sifakis E; Hartman J
Meeting abstract: CANCER RESEARCH. 2024;84(9):po2-07-06-po2-07-06
Multimodal learning predictor of HER2-positive breast cancer therapy response in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Sifakis E; Manikis G; Salgkamis D; Tsiknakis N; Harbers L; Crosetto N; Bergh J; Matikas A; Hatschek T; Foukakis T
Preprint: RESEARCH SQUARE. 2024
Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study
Kjällquist U; Tsiknakis N; Acs B; Margolin S; Kessler LE; Levy S; Ekholm M; Lundgren C; Olsson E; Lindman H; Valachis A; Hartman J; Foukakis T; Matikas A
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2024;200:113830
Multiomic profiling reveals predictive molecular characteristics of response to neoadjuvant antibody-drug conjugate versus chemotherapy and dual HER2 blockade in HER2 positive breast cancer
Foukakis T; Wang K; Zerdes I; Zhu Y; Sifakis E; Tsiknakis N; Manikis G; Salgkamis D; Harbers L; Bergh J; Johansson H; Crosetto N; Lehtio J; Matikas A; Hatschek T
Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2024;47:36
RESCUER - Data harmonization of multiple clinical trials - challenges and chances
Lehle S; Ernst M; Braso-Maristany F; Prat A; Engebraten O; Hatschek T; Foukakis T; Kyte JA; Rubner M; Uhrig S; Beckmann M; Fasching PA; Kristensen VN; Huebner H
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023;192:104189
The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2023;34:s307-s308
Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up
Zerdes I; Matikas A; Mezheyeuski A; Acs B; Johansson H; Manikis G; Boyaci C; Boman CE; Poncet C; Ignatiadis M; Bai Y; Rimm D; MacGrogan G; Cameron DA; Bergh J; Bonnefoi H; Foukakis T
Conference publication: ANNALS OF SURGICAL ONCOLOGY. 2023;30(SUPPL 2):S295-S296
Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early TNBC: Surgical Outcomes from the Phase 3 KEYNOTE-522 Study
Kuemmel S; Schmid P; Harbeck N; Takahashi M; Untch M; Boileau J-F; Cortes J; McArthur H; Dent R; O'Shaughnessy J; Pusztai L; Foukakis T; Park YH; Hui R; Cardoso F; Denkert C; Zhu Y; Pan W; Karantza V; Fasching PA
Editorial comment: MOLECULAR ONCOLOGY. 2023;17(4):545-547
The interplay between eosinophils and T cells in breast cancer immunotherapy
Zerdes I; Matikas A; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary File S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S3 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Figure S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S1 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Data from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Other: AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR). 2023
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Conference publication: BREAST. 2023;68:S63-S64
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study
Kuemmel S; Schmid P; Harbeck N; Takahashi M; Untch M; Boileau J-F; Cortes J; McArthur H; Dent R; O'Shaughnessy J; Pusztai L; Foukakis T; Park YH; Hui R; Cardoso F; Denkert C; Zhu Y; Pan W; Karantza V; Fasching P
Meeting abstract: CANCER RESEARCH. 2023;83(5):p2-21-02-p2-21-02
Longitudinal tumor-immune microenvironment changes in patients with clinical luminal A early breast cancer treated with neoadjuvant palbociclib and endocrine therapy: results from the Swedish randomized PREDIX Luminal A trial
Zerdes I; Salgkamis D; Matikas A; Selander L; Wang K; Tzoras E; Sifakis E; Agartz S; Chen X; Hellstrom M; Hartman J; Bergh J; Foukakis T; Hatschek T
Meeting abstract: CANCER RESEARCH. 2023;83(5):p5-02-20-p5-02-20
Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
Wang K; Zhu Y; Zerdes I; Matikas A; Sifakis E; Salgkamis D; Bjohle J; Elinder E; Margolin S; Campos AB; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Johansson H; Hellstrom M; Azavedo E; Hartman J; Bergh J; Hatschek T; Foukakis T
Preprint: MEDRXIV. 2023
Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients
Castresana-Aguirre M; Johansson A; Matikas A; Foukakis T; Lindström L; Tobin N
Book chapter: INTRODUCTION TO ARTIFICIAL INTELLIGENCE: IMAGING INFORMATICS FOR HEALTHCARE PROFESSIONALS. 2023;p. 13-37
Using Commercial and Open-Source Tools for Artificial Intelligence: A Case Demonstration on a Complete Radiomics Pipeline
Stamoulou E; Spanakis C; Nikiforaki K; Karantanas AH; Tsiknakis N; Matikas A; Foukakis T; Manikis GC
Conference publication: NUCLEAR MEDICINE AND BIOLOGY. 2023;126:S46
Preclinical evaluation of [⁸⁹Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC)
Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran T
Book chapter: BREAST CANCER MANAGEMENT FOR SURGEONS. 2023;p. 203-218
Principles of Primary Systemic Therapy
Foukakis T; Matikas A; Valachis A
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843
Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Review: JOURNAL OF IMAGING. 2022;8(11):303
Harmonization Strategies in Multicenter MRI-Based Radiomics
Stamoulou E; Spanakis C; Manikis GC; Karanasiou G; Grigoriadis G; Foukakis T; Tsiknakis M; Fotiadis DI; Marias K
Conference publication: EUROPEAN JOURNAL OF CANCER. 2022;175:S40
A multimodal approach for the management of co-morbid cardiotoxicity in the elderly breast cancer patients
Karanasiou G; Grigoriadis G; Alexandraki A; Antoniades A; Brown C; Bucur A; Cipolla C; Economopoulou P; Foukakis T; Goossens J; Keramida K; Lakkas L; Marias K; Naka K; Papakonstantinou A; Pravettoni G; Ribnikar D; Seruga B; Zacharia M; Tsiknakis M; Fotiadis DI
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S614
The prognostic importance of high HER2 copy numbers and high HER2/CEP17 ratio in trastuzumab-treated early breast cancer
Ronnlund C; Robertson S; Sifakis EG; Fredriksson I; Foukakis T; Hartman J
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S1306
Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction
Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Lovrot J; Tay A; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Conference publication: CANCER RESEARCH. 2022;82(12_Supplement):2045
Abstract 2045: Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer
Thomas N; Garaud S; Langouo M; Zerdes I; Sofronii D; Boisson A; Foukakis T; De Wind A; Salgado R; Awada A; Willard-Gallo K
Conference publication: CANCER RESEARCH. 2022;82(12)
Spatial organization of the immune microenvironment after neoadjuvant treatment of breast cancer
Thomas N; Garaud S; Langouo M; Zerdes I; Sofronii D; Boisson A; Foukakis T; De Wind A; Salgado R; Awada A; Willard-Gallo K
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12598
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):e12620
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16_suppl):593
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Grybäck P; Bjöhle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
Zhu Y; Wang K; Zerdes I; Matikas A; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Bergh JCS; Hatschek T; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.
Zerdes I; Zhu Y; Tzoras E; Matikas A; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2022;40(16)
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
Matikas A; Johansson H; Gryback P; Bjohle J; Lekberg T; Fredholm H; Acs B; Elinder E; Isaksson-Friman E; Agartz S; Hellstrom M; Zerdes I; Hartman J; Bergh JCS; Hatschek T; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33:S125
Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer
Wang K; Zerdes I; Sifakis EG; Johansson HJ; Mezheyeuski A; Lehtio J; Bergh J; Hatschek T; Matikas A; Foukakis T
Review: CANCERS. 2022;14(8):1999
Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Meeting abstract: CANCER RESEARCH. 2022;82(4):p1-02-03-p1-02-03
Tumor-infiltrating lymphocytes but not HER2 copy number or ratio show prognostic value in trastuzumab-treated HER2-positive breast cancer
Robertson S; Ronnlund C; Fredriksson I; Foukakis T; Hartman J
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(12):1457-1459
Adjuvant abemaciclib for high-risk breast cancer: the story continues
Spring L; Matikas A; Bardia A; Foukakis T
Review: ESMO OPEN. 2021;6(6):100289
The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis
Paakkola N-M; Karakatsanis A; Mauri D; Foukakis T; Valachis A
Conference publication: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2021;9:A364
EFFECTS OF PEMBROLIZUMAB ON THE TUMOR MICROENVIRONMENT (TME) AFTER ONE PRESURGERY TREATMENT CYCLE IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (TNBC): PHASE 1B KEYNOTE-173 STUDY
Schmid P; Park YH; Munoz-Couselo E; Kim S-B; Sohn J; Im S-A; Holgado E; Foukakis T; Kuemmel S; Dent R; Sun Y; Huang L; Yearley J; Jelinic P; Karantza V; Cortes J
Corrigendum: JAMA ONCOLOGY. 2021;7(9):1405-1406
Errors in Abstract and Results.
Review: CANCER TREATMENT REVIEWS. 2021;99:102257
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
Boman C; Zerdes I; Martensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Editorial comment: BREAST CARE. 2021;16(4):422-428
Expert Discussion: HER2-Positive Breast Cancer
Foukakis T; Matikas A; Oikonomidou O; Andreopoulou E; Mavroudis D
Conference publication: ANNALS OF ONCOLOGY. 2021;32:S70-S71
Women with short survival after diagnosis of metastatic breast cancer: A population-based registry study
Boman CE; Kessler LE; Bergh J; Matikas A; Foukakis T
Conference publication: CANCER RESEARCH. 2021;81(4_Supplement):ps18-27-ps18-27
Abstract PS18-27: Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(2):129-132
SOLAR1s: alpelisib returns to earth?
Matikas A; Foukakis T
Conference publication: CANCER RESEARCH. 2021;81(4)
Integrated immuno-genomic analyses in early breast cancer: Results from the Scandinavian breast group 2004-1 (SBG-2004-1) randomized phase II trial
Zerdes I; Simonetti M; Matikas A; Harbers L; Zhang N; Salgkamis D; Agartz S; Zacharouli M; Moreno-Ruiz P; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Conference publication: ANNALS OF ONCOLOGY. 2020;31:S1241-S1242
KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC)
Dent R; Cortes J; Pusztai L; McArthur HL; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Jia L; Jensen E; Karantza V; Aktan G; O'Shaughnessy J; Schmid P
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S328
Heterogeneity of PD-L1 expression at the protein and mRNA levels in early breast cancer
Zerdes I; Stogiannitsi M; Bergh J; Hatschek T; Foukakis T; Matikas A
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15_suppl):545
PD-1 protein and gene expression in early breast cancer: Prognostic implications.
Zerdes I; Matikas A; Lövrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)
One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.
Brandberg Y; Foukakis T; Andersson A; Bjohle J; Bosch A; Carlsson L; Einbeigi Z; Fredholm H; Isaksson-Friman E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Bergh JCS; Hatschek T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15)
PD-1 protein and gene expression in early breast cancer: Prognostic implications.
Zerdes I; Matikas A; Lovrot J; Sifakis EG; Richard F; Sotiriou C; Rassidakis GZ; Bergh JCS; Valachis A; Foukakis T
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S49
PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels
Hatschek T; Andersson A; Bjohle J; Bosch A; Carlsson L; Dreifaldt AC; Einbeigi Z; Elinder E; Fredholm H; Isaksson-Friman E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Zerdes I; Foukakis T; Hartman J; Brandberg Y; Bergh J
Conference publication: ANNALS OF ONCOLOGY. 2020;31:S54
Factors associated with mastectomy in women with small residual tumour after neoadjuvant chemotherapy for breast cancer
Bernell E; Duinmeijer A; Altena R; Foukakis T; Fredholm H
Conference publication: ANNALS OF SURGICAL ONCOLOGY. 2020;27(SUPPL 2):S337-S338
Axillary Staging in the Setting of a Preoperative Diagnosis of Ductal Cancer In Situ (DCIS): Results of an International Expert Panel and a Critical Guideline Performance Using Frequentist and Bayesian Analysis
Karakatsanis A; Foukakis T; Karlsson P; Mamounas E; Chagpar A; Boyages J; Rubio I; Naume B; Mauri D; van der Wall E; Shah C; Kwong A; McAuliffe P; Gentilini O; Ignatiadis M; Schlichting E; Zgajnar J; Meani F; Tasoulis MK; Whitworth P; Weber W; Charalampoudis P; Gulluoglu B; Pistioli L; Tvedskov TF; Leidenius M; Mann B; Witkamp A; Wyld L; di Micco R; Markopoulos C; Valachis A; Warnberg F
Corrigendum: BRITISH JOURNAL OF CANCER. 2020;122(7):1119
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Müller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graiff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J; SOLE Investigators
Meeting abstract: CANCER RESEARCH. 2020;80(4):p3-08-07-p3-08-07
Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer
Kouvaraki M; Sifakis EG; Zerdes I; Herold N; Bergh J; Rassidakis GZ; Foukakis T
Conference publication: ANNALS OF ONCOLOGY. 2019;30:86
Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Papakonstantinou A; Matikas A; Hellstrom M; Johansson H; Steger G; Greil R; Loibl S; Gnant M; Moebus V; Untch M; Foukakis T; Bergh J
Conference publication: ANNALS OF ONCOLOGY. 2019;30
Administration of chemotherapy for metastatic breast cancer near the end of life: A population registry study
Kessler LE; Sigfridsson J; Bergh J; Foukakis T; Matikas A
Conference publication: ANNALS OF ONCOLOGY. 2019;30:853-854
KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Schmid P; Cortes J; Dent R; Pusztai L; McArthur HL; Kuemmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Jia L; Karantza V; Zhao J; Aktan G; O'Shaughnessy J
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):550
Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2-early breast cancer.
Zerdes I; Sifakis EG; Tobin N; Bergh JCS; Matikas A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):583
Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.
Brandberg Y; Andersson A; Bjohle J; Bosch A; Carlsson L; Dreifaldt AC; Einbeigi Z; Fredholm H; Isaksson-Friman E; Foukakis T; Elinder E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Bergh JCS; Hatschek T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):501
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
Bergh JCS; Andersson A; Bjohle J; Bosch A; Carlsson L; Dreifaldt AC; Einbeigi Z; Fredholm H; Isaksson-Friman E; Foukakis T; Elinder E; Hellstrom M; Johansson H; Lekberg T; Lindman H; Maes C; Brandberg Y; Hatschek T
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):e14284
Prognostic implications of PD-L1 expression in breast cancer at the protein and mRNA levels.
Matikas A; Zerdes I; Lovrot J; Richard F; Sotiriou C; Bergh JCS; Valachis A; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):553
Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
Foukakis T; Papakonstantinou A; Matikas A; Bengtsson N-O; Malmstrom P; Hedayati E; Steger GG; Untch M; Hubbert L; Johansson H; Hellstrom M; Gnant M; Loibl S; Greil R; Moebus V; Bergh JCS
Review: CANCERS. 2019;11(5):E628-628
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chretien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2019;133:S310-S311
5 year results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial
Bosma S; van der Leij F; Vreeswijk S; van der Vijver M; Rivera S; Foukakis T; van den Bongard D; Rutgers E; Scholten A; Bartelink H; Elkhuizen P
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397
Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology
Matikas A; Foukakis T; Bergh J
Conference publication: CANCER RESEARCH. 2019;79(4):p3-10-09-p3-10-09
Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro) plus chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
Loi S; Schmid P; Cortes J; ark YH; Munoz-Couselo E; Kim S-B; Sohn J; Im S-A; Holgado E; Foukakis T; Kuemmel S; Dent R; Wang A; Aktan G; Karantza V; Salgado R
Conference publication: CANCER RESEARCH. 2019;79(4):pd5-01-pd5-01
KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC)
Schmid P; Park YH; Munoz-Couselo E; Kim S-B; Sohn J; Im S-A; Holgado E; Foukakis T; Kuemmel S; Dent R; Yin L; Ding Y; Tryfonidis K; Cortes J
Meeting abstract: CANCER RESEARCH. 2019;79(4):p2-08-25-p2-08-25
PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer
Zerdes I; Sifakis E; Matikas A; Tobin NP; Charlotte R; Rassidakis GZ; Bergh J; Foukakis T
Preprint: SSRN ELECTRONIC JOURNAL. 2019
Pembrolizumab Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim S-B; Sohn J; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Editorial comment: ANNALS OF ONCOLOGY. 2018;29(12):2278-2280
Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?
Foukakis T
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281
RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Matikas A; Foukakis T; Bergh J
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Editorial comment: LANCET ONCOLOGY. 2018;19(7):850-852
Ribociclib in premenopausal women with advanced breast cancer
Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):538
Dose tailoring of breast cancer adjuvant chemotherapy aiming at avoiding both over and undertreatment: Results from the prospective PANTHER study.
Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellstrom M; Malmstrom P; Gnant M; Loibl S; Bergh JCS
Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Matikas A; Margolin S; Hellstrom M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Matikas A; Foukakis T; Bergh J
Conference publication: ANNALS OF ONCOLOGY. 2017;28
Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
Matikas A; Lovrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Erlandsson A; Hatschek T; Foukakis T
Conference publication: ANNALS OF ONCOLOGY. 2017;28
CTCA toxicity scoring and EORTC quality of life questionnaire: A comparison of physicians' and patients' scoring of toxicity in the "Panther trial"
Brandberg Y; Loibl S; Foukakis T; Johansson H; Gnant M; Singer CF; von Minckwitz G; Bengtsson N-O; Karlsson E; Mlineritsch B; Hellstrom M; Steger G; Carlsson L; Egle D; Greil R; Bergh J
Conference publication: ANNALS OF ONCOLOGY. 2017;28
Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register
Falato C; Eriksson L; Sofiadis A; Taylor SK; Nordblom A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Conference publication: CANCER RESEARCH. 2017;77:418
Adaptive resistance to chemotherapy in triple-negative breast cancer revealed by single cell DNA and RNA sequencing
Kim C; Gao R; Sei E; Brandt R; Crosetto N; Foukakis T; Navin N
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017;114:91-101
Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine
Matikas A; Foukakis T; Bergh J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e23088
Regulation of PD-L1 in breast cancer
Zerdes I; Tsesmetzis N; Lovrot J; Rolny C; Bergh JCS; Rassidakis G; Foukakis T
Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2017;17(4):319-326
Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
Matikas A; Foukakis T; Michalakis I; Georgoulias V
Conference publication: CANCER RESEARCH. 2017;77:p1-07-07-p1-07-07
Gene expression signatures and immunohistochemical subtypes add prognostic value to each other
Lundberg A; Lindstrom LS; Falato C; Carlson JW; Foukakis T; Czene K; Bergh J; Tobin NP
Conference publication: EUROPEAN JOURNAL OF CANCER. 2017;72:S3
Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study)
Brandberg Y; Foukakis T; Johansson H; Hellstrom M; Gnant M; Loibl S; Bergh J
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(1):121-122
Estradiol Level and Menopause Reply
Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):1035
The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxel-Health-related quality of life during ongoing therapy.
Brandberg Y; Johansson H; Hellstrom M; Foukakis T; Gnant M; von Minckwitz G; Bergh JCS
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):1002
PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.
Bergh JCS; Foukakis T; von Minckwitz G; Bengtsson N-O; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger GG; Karlsson E; Carlsson L; Loibl S; Untch M; Hellstrom M; Johansson H; Malmstrom P; Gnant M; Greil R; Moebus V
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(14):1386-1387
A 21-Gene Expression Assay in Breast Cancer
Foukakis T; Falato C; Bergh J
Conference publication: CANCER RESEARCH. 2016;76:ot2-04-03-ot2-04-03
An intrinsic subtype-based platform of translational randomized phase II trials of response-guided neoadjuvant therapy in breast cancer (PREDIX)
Foukakis T; Hellstrom M; Johansson H; Bergh J; Hatschek T
Review: JOURNAL OF INTERNAL MEDICINE. 2015;278(6):545-570
The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer
Tobin NP; Foukakis T; De Petris L; Bergh J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15):1044
Gene expression of metastatic biopsies for prediction of response to palliative chemotherapy in breast cancer
Foukakis T; Lorent J; Tobin N; Lindstrom LS; Bergh JCS; Hatschek T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2015;33(15)
Immunohistochemistry-based subtypes and gene expression signatures as predictors of prognosis in metastatic breast cancer
Falato C; Tobin N; Lorent J; Lindstrom LS; Bergh JCS; Foukakis T
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2015;115:S188-S189
First results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) trial
Bosma SCJ; Van der Leij F; Van de Vijver MJ; Rivera S; Foukakis T; Van den Bongard HJGD; Vreeswijk SAOJ; Bartelink H; Rutgers EJ; Elkhuizen PHM
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(1):84-85
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Foukakis T; Lovrot J; Bergh J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):e22120
Sequential metastatic biopsies and functional imaging in breast cancer
Foukakis T; Lovrot J; Sandqvist P; Xie H; Lindstroem LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh JCS
Conference publication: CANCER RESEARCH. 2013;73:p6-06-10-p6-06-10
Prognostic role of Ki67 determined on metastatic biopsies in patients with advanced breast cancer
Falato C; Lorent J; Kessler L; Karlsson E; Wilking U; Wright P; Skoog L; Bergh J; Foukakis T
Meeting abstract: CANCER RESEARCH. 2013;73:p6-06-17-p6-06-17
Gene signature model predicts metastatic onset better than standard clinical markers - Nested case-control design uniquely enables enrichment for biologically relevant features
Lindstrom LS; Jauhiainen A; Wilking U; Foukakis T; Astrom G; Czene K; Bergh J
Conference publication: CANCER RESEARCH. 2013;73:ot1-2-03-ot1-2-03
A prospective randomized phase II study to identify predictive biomarkers and mechanisms of resistance in patients with HER2-negative metastatic breast cancer treated with the combination of bevacizumab and paclitaxel
Foukakis T; Hartman J; Stone-Elander S; Jacobsson H; Bergh J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15)
Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience
Kessler L; Bergh J; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(15)
A retrospective safety analysis of adult patients treated with high-dose methotrexate for osteosarcoma in Stockholm, Sweden.
Alm D; Stragliotto CL; Folin A; Bergh J; Foukakis T
Conference publication: BREAST. 2011;20:S28-S29
PROGNOSTIC ROLE OF KI67 DETERMINED ON METASTATIC TISSUE OF PATIENTS WITH ADVANCED BREAST CANCER
Falato C; Lindstrom L; Hosseini S; Czene K; Hall P; Sylwan M; Skoog L; Bergh J; Foukakis T
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(15):1058
Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden.
Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Conference publication: CANCER RESEARCH. 2009;69
Proteomic studies in well differentiated thyroid tumors
Sofiadis A; Zedenius J; Wallin G; Foukakis T; Hoog A; Orre L; Lehtio J; Larsson C
Book chapter: CLINICAL ENDOCRINE ONCOLOGY. 2008;p. 124-129
Pathogenesis of Thyroid Cancer
Zedenius J; Foukakis T
Conference publication: HORMONE RESEARCH IN PAEDIATRICS. 2007;68:41
MIB-1 proliferation index in thyroid tumors' fine needle aspiration cytology (FNAC):: A prognostic tool?
Sofiadis A; Larsson C; Wallin G; Zedenius J; Foukakis T; Hoog A; Tani E; Kjellman P
Review: ACTA ONCOLOGICA. 2007;46(3):277-285
Advances in the treatment of patients with gastric adenocarcinoma
Foukakis T; Lundell L; Gubanski M; Lind PA
Conference publication: CANCER RESEARCH. 2006;66(8)
Molecular cytogenetic characterization of anaplastic thyroid carcinoma
Lee J-J; Foukakis T; Lui W-O; Hashemi J; Heldin N-E; Grimelius L; Wallin G; Hoog A; Larsson C
Conference publication: CANCER RESEARCH. 2006;66(8)
Anti-tumorigenic effects of RASSF5 (NORE1) in human pheochromocytomas
Geli J; Kiss N; Natalishvili N; Foukakis T; Lanner F; Bertil H; Backdahl M; Farnebo F; Larsson C
Doctoral thesis: 2005
Basic and translational studies of follicular thyroid neoplasia
Foukakis T
Conference publication: AMERICAN JOURNAL OF HUMAN GENETICS. 2003;73(5):219
Cytogenetic characterization of thyroid tumors and cell lines using comparative genomic hybridization, spectral karyoyping and G-banding
Foukakis T; Thoppe SR; Lagercrantz S; Dwight T; Svensson A; Liu WO; Wallin G; Zedenius J; Larsson C
Visa fler

Forskningsbidrag

Antibody-based TROP-2 targeted radiopharmaceuticals for improved theranostics of metastatic solid cancers
Swedish Research Council
1 January 2024 - 31 December 2027
Illuminating the origin and consequences of genomic structural variation in cancer
Swedish Research Council
1 January 2023 - 31 December 2026
Integrative digital diagnostics for therapy optimization in early breast cancer
Swedish Research Council
1 January 2022 - 31 December 2025
Foukakis, Theodoros – Integrative machine learning predictive models for neoadjuvant therapy optimization in breast cancer
Swedish Cancer Society
1 January 2022
Randomized Trials on Biology-Driven De-escalation of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE master protocol
Swedish Research Council
1 December 2020 - 31 December 2024
Treatment of oligometastatic breast cancer – a randomised translational phase 3 trial comparing stereotactic ablative radiotherapy and systemic treatment with systemic treatment alone "TAORMINA"
Swedish Research Council
1 December 2020 - 4 March 2024
Optimizing treatment in HER2 positive breast cancer through insights in tumor biology
Swedish Research Council
1 January 2019 - 31 December 2021
Refining pre-operative systemic therapy through repeated therapy evaluation and a cross-over design in a prospective randomized phase II study for primary HER2-amplified breast cancer.
Swedish Research Council
1 January 2019 - 31 March 2021
Optimization of breast cancer treatment through better understanding of tumor biology
Swedish Cancer Society
1 January 2018
Translational studies for the development of predictive biomarkers in breast cancer
Swedish Cancer Society
1 January 2017
Translational studies for the development of predictive biomarkers in breast cancer
Swedish Cancer Society
1 January 2016
Translational studies for the development of predictive biomarkers in breast cancer
Swedish Cancer Society
1 January 2015

Anställningar

Professor/Överläkare, Onkologi-Patologi, Karolinska Institutet, 2025-
Universitetslektor/Överläkare, Onkologi-Patologi, Karolinska Institutet, 2020-2025

Examina och utbildning

Docent, Onkologi, Karolinska Institutet, 2014
MEDICINE DOKTORSEXAMEN, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2005

Handledning

Behnaz Khalilzadeh Binicy, Studies on controversies in the treatment of early breast cancer., 2024-
Maria Angeliki Toli, Prognostic and predictive markers after neoadjuvant therapy in breast cancer, 2023-

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Handledning

Nyheter från KI

Kalenderhändelser från KI